Financial Services for HealthTech & Life Sciences Companies
Raftel Strategy provides outsourced CFO services, accounting, FP&A, and strategic advisory for healthtech and life sciences companies operating in regulated, capital-intensive environments. We support companies navigating long development timelines, milestone-based funding, regulatory oversight, and the financial complexity of deploying capital into R&D, clinical validation, and commercialization before predictable revenue exists. Our clients range from early-stage healthtech startups building their first financial models to growth-stage life sciences companies managing multi-entity operations across the US and Israel. We bring structured financial leadership that connects your operational roadmap to a defensible capital strategy.
Why HealthTech and Life Sciences Companies Need Specialized Financial Support
HealthTech and life sciences companies operate on a fundamentally different financial timeline than most startups. Capital is deployed into research, clinical development, product validation, and regulatory processes long before revenue materializes. Every dollar spent is an investment against a future milestone that may take months or years to reach.
This creates financial dynamics that generic accounting firms and generalist CFOs are not equipped to handle.
A life sciences company burning $150,000 a month on clinical trials needs to know exactly how many months of runway it has under three different enrollment scenarios, not a single-line burn rate calculation. A healthtech startup approaching an FDA submission needs financial reporting that ties capital deployment directly to regulatory milestones so investors can see progress in financial terms, not just scientific ones. A company with a 24-month development horizon and 18 months of cash needs to know today, not in 6 months, whether the gap requires a bridge round or an operational adjustment.
In regulated environments, the financial infrastructure behind the company matters as much as the science or product. One missed compliance requirement in your reporting can delay a partnership. One undisciplined forecast can erode investor confidence at exactly the wrong moment. One cash flow miscalculation can force a down round that was entirely avoidable.
Healthtech financial consulting is not about making the books look clean. It is about building a financial function that protects capital, communicates progress, and gives leadership the visibility to make decisions before they become emergencies.
How We Work With HealthTech & Life Sciences Companies
Raftel embeds directly with your leadership team. We operate as your outsourced CFO and finance function, bringing financial discipline to environments where timelines are long, capital is finite, and the margin for error is narrow. Some clients come to us pre-revenue with a scientific team and no finance infrastructure at all. Others have basic accounting in place but need financial leadership to connect the numbers to strategy. We fit into either model.
Our focus is straightforward: align your financial models with your regulatory and development roadmap so every capital decision is informed, defensible, and forward-looking.
Strategic finance and CFO leadership
We guide capital strategy, board reporting, and executive decision-making. For healthtech and life sciences companies, that means modeling around clinical milestones, regulatory timelines, and the funding events that need to happen between them. We do not build a single-scenario forecast and call it a plan. We model multiple paths, stress-test assumptions against development risk, and show leadership the financial implications of delays, accelerations, and scope changes before they happen.
Accounting and financial reporting built for regulated environments
In regulated industries, financial reporting must withstand scrutiny from investors, auditors, partners, and oversight bodies. We build clean, structured close processes with compliance-aware reporting that satisfies multiple stakeholders simultaneously. Every allocation, every recognition decision, and every disclosure is documented and defensible.
Healthtech financial modeling tied to development milestones
We build financial models that reflect how healthtech and life sciences companies actually operate: burn rates that shift by development phase, revenue assumptions tied to regulatory approvals and commercialization timelines, and funding requirements mapped to specific milestones. This is the model your investors need to see, because it shows you understand the relationship between capital, time, and risk.
Life sciences budgeting and forecasting
We align budgets with R&D spend, operational scaling, and the milestones that trigger the next phase of growth or the next funding conversation. For companies managing multiple workstreams across research, development, and early commercialization, this means forecasting that reflects where resources are actually going and whether the allocation matches the strategic priorities.
Cash flow management for long development cycles
Healthtech cash flow management is about timing and discipline. We forecast burn relative to regulatory milestones, funding events, and commercialization plans so leadership always knows how long current capital truly lasts. Not approximately. Not optimistically. Under realistic assumptions with clearly defined sensitivities.
Investor reporting that communicates progress
Investors in healthtech and life sciences are evaluating milestone achievement as much as financial performance. We build investor reporting that connects capital deployment to measurable progress, communicates efficiency clearly, and gives your investors confidence that their capital is being managed with discipline.
Supporting HealthTech Companies Across the US and Israel
Many healthtech and life sciences companies operate across borders from inception. Research teams in Israel. A US entity for regulatory submissions and commercial operations. Investors and partners in both countries. Clinical work spanning multiple jurisdictions.
Raftel provides cross-border financial support for healthtech and life sciences companies with US and Israel entities. We align accounting, reporting, and financial strategy across both geographies so leadership operates from one set of numbers. We coordinate with local tax advisors, auditors, and compliance teams in both countries. And we structure entity-level reporting and intercompany arrangements so cross-border operations do not create compliance risk or slow down decision-making.
For healthtech companies operating internationally in regulated environments, financial alignment across entities is not just an operational preference. It is a requirement for maintaining credibility with investors, partners, and oversight bodies in both jurisdictions.
.jpg)
Proof in Practice
Raftel has supported healthtech and life sciences companies through fundraising, regulatory milestones, and cross-border structuring. We have built the financial models that connected R&D roadmaps to capital strategy, the reporting frameworks that satisfied both investors and regulatory requirements, and the accounting infrastructure that scaled as companies moved from development into commercialization. Our clients stay because the finance function we build becomes part of how they plan, communicate, and grow.
Frequently Asked Questions
Get Started
If you are building in healthtech or life sciences and need financial structure that matches the regulatory and capital intensity of your industry, reach out. Tell us your stage, your next milestone, and what your current finance function is not giving you. We will tell you what needs to change.